Vor Biopharma (VOR) said late Wednesday it entered a license agreement with RemeGen for global rights, excluding Greater China, to develop and commercialize telitacicept for autoimmune conditions including generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis.
The company will initially pay RemeGen $125 million, including a $45 million upfront payment and $80 million in warrants to purchase its common stock. The agreement also includes regulatory and commercial milestones of over $4 billion and tiered royalties.
RemeGen is enrolling participants in a global phase 3 trial for telitacicept, with initial results expected in the first half of 2027.
Vor Bio also named Jean-Paul Kress as chief executive officer and board chairman, succeeding Robert Ang, who will remain as a strategic advisor through October.
Separately, the company said it plans to raise $175 million in gross proceeds through a private placement to advance its clinical pipeline and support general corporate needs. Upon closing, Vor Bio will issue prefunded warrants to purchase 700 million common shares at $0.25 per warrant.
The financing is expected to close Friday.
Shares of Vor Biopharma were up nearly 3% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.